Download PDF
Thromb Haemost 1993; 70(05): 822-825
DOI: 10.1055/s-0038-1649677
Platelets
Schattauer GmbH Stuttgart

Synergistic Antiplatelet Effect of Ridogrel, a Combined Thromboxane Receptor Antagonist and Thromboxane Synthase Inhibitor, and UDCG-212, a cAMP-Phosphodiesterase Inhibitor

B Hoet
The Center for Molecular and Vascular Biology, University Leuven, Leuven, Belgium
,
J Arnout
The Center for Molecular and Vascular Biology, University Leuven, Leuven, Belgium
,
H Deckmyn
The Center for Molecular and Vascular Biology, University Leuven, Leuven, Belgium
,
J Vermylen
The Center for Molecular and Vascular Biology, University Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 08 December 1992

Accepted after revision 29 June 1993

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor (1), inhibits platelet aggregation. Following stimulation with arachidonic acid, cAMP-levels are increased in human platelets preincubated with ridogrel, this is due to the known reorientation of the metabolism of the formed endoperoxides towards adenylate cyclase stimulating prostaglandins.

Pretreatment of resting platelets with UDCG-212, a cAMP-phosphodiesterase inhibitor (2), also inhibits platelet aggregation induced by arachidonic acid, concomitant with an increase in cAMP levels, due to an inhibition of its breakdown. Under basal conditions, cAMP also is increased.

By combining the two drugs, a more than additive action was observed on platelet aggregation and on both resting and stimulated platelet cAMP content. The appropriate combination may result in a more effective antiplatelet strategy.

 

  • References

  • 1 Hoet B, Falcon C, De ReysS, Arnout J, Deckmyn H, Vermylen J. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood 1990; 75: 646-653
    PubMedGoogle Scholar
  • 2 Berger G, Meyer W, Scholz H, Starbaty J. Effects of the benzimidazole derivatives pinmobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-OXO-4-dihydro-2H-6-pyridarinyl)benzimidazol HC1 on phosphodiesterase activity and force of contraction of guinea pig hearts. Arzneim Forsch 1985; 35: 1668-1673
    PubMedGoogle Scholar
  • 3 Hamberg MJ, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998
    CrossrefPubMedGoogle Scholar
  • 4 Brass LF, Shaller CC, Belmonte EJ. Inositol 1,4,5-trisphosphate induced granule secretion in platelets. Evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin. J Clin Invest 1987; 79: 1269-1275
    CrossrefPubMedGoogle Scholar
  • 5 Rybicki JP, Le BretonGC. Prostaglandin H2 directly lowers human platelet cAMP levels Thromb Res 1983; 30: 407-414
    CrossrefPubMed
  • 6 Avdonin PV, Svitina-Ulutina IV, Ley tinVL, Thachuk VA. Interaction of stable prostaglandin endoperoxide analogs U46619 and U44069 with human platelet membranes: coupling of receptors with high-affinity GTPase and adenylate cyclase. Thromb Res 1985; 40: 101-112
    CrossrefPubMedGoogle Scholar
  • 7 Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 1987; 80: 1435-1445
    CrossrefPubMedGoogle Scholar
  • 8 Brass LF, Woolkalis MJ, Manning DR. Interactions in platelets between G-proteins and the agonists that stimulate phospholipase C and inhibit adenylyl cyclase. J Biol Chem 1988; 263: 5348-5355
    PubMedGoogle Scholar
  • 9 Vermylen J, Defreyn G, Carreras LO, Machin SJ, Van SchaerenJ, Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet 1981; i: 1073-1075
    PubMedGoogle Scholar
  • 10 Gresele P, Deckmyn H, Huybrechts E, Vermylen J. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2 . Biochem Pharmacol 1984; 33: 2083-2088
    CrossrefPubMedGoogle Scholar
  • 11 Mills DCB, MacFarlane DE. Stimulation of human platelet adenylate cyclase by prostaglandin D2 . Thromb Res 1974; 5: 401-412
    CrossrefPubMedGoogle Scholar
  • 12 Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry MJ. Effect of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res 1980; 20: 219-230
    CrossrefPubMedGoogle Scholar
  • 13 Bertele V, Cerletti C, Schieppati A, Di MinnoG, de GaetanoG. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet 1981; i: 1057-1058
    PubMedGoogle Scholar
  • 14 FitzGerald GA, Reilly IA, Pedersen AK. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation 1985; 72: 1194-1201
    CrossrefPubMedGoogle Scholar
  • 15 Sills T, Heptinstall S. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour. Thromb Haemostas 1986; 55: 305-308
    PubMedGoogle Scholar
  • 16 Gresele P, Deckmyn H, Amout J, Lemmens J, Janssens W, Vermylen J. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet 1984; i: 991-994
    PubMedGoogle Scholar
  • 17 Bertele V, de GaetanoG. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Eur J Pharmacol 1982; 85: 331-333
    CrossrefPubMedGoogle Scholar
  • 18 Gresele P, Deckmyn H, Amout J, Nenci GG, Vermylen J. Characterization of N, N’-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thromb Haemostas 1989; 61: 479-484
    PubMedGoogle Scholar
  • 19 De ClerckF, Beetens J, de Chaffoy de Courcelles D, Freyne E, Janssen P. R68070: Thromboxane A2 synthase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule I. Biochemical profile in vitro. Thromb Haemostas 1989; 61: 35-42
    PubMedGoogle Scholar
  • 20 Bom GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178
    CrossrefPubMedGoogle Scholar
  • 21 Krishna G, Weiss B, Brodie BB. A simple, sensitive method for the assay of adenylyl cyclase. J Pharmacol Exp Ther 1968; 163: 379-385
    PubMedGoogle Scholar
  • 22 Salzman EW, Neri LL. Cyclic 3’,5’-adenosine monophosphate in human blood platelets. Nature 1969; 224: 609-610
    CrossrefPubMedGoogle Scholar
  • 23 Berenbaum MC. The expected effect of a combination of agents: the general solution. J Theoret Biol 1985; 114: 413-431
    CrossrefPubMedGoogle Scholar
  • 24 Haslam RJ, Davidson MML, Davies T, Lynham JA, McClenaghan MD. Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucl Res 1978; 9: 533-552
    PubMedGoogle Scholar
  • 25 Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2 . Thromb Res 1982; 26: 389-400
    CrossrefPubMedGoogle Scholar
  • 26 Deckmyn H, Van HoutteE, Verstraete M, Vermylen J. Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom. Biochem Pharmacol 1983; 32: 2757-2767
    CrossrefPubMedGoogle Scholar
  • 27 Gresele P, Blockmans D, Deckmyn H, Vermylen J. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. J Pharmacol Exp Ther 1988; 246: 301-307
    PubMedGoogle Scholar
  • 28 Smith JB. Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase Thromb Res 1982; 28: 477-485
    CrossrefPubMed
  • 29 Martinez GR, Walker KAM, Hirschfeld DR, Bruno U, Yang DS, Maloney PJ. 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP-phosphodiesterase. J Medicin Chem 1992; 35: 620-628
    PubMedGoogle Scholar
  • 30 Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Debianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. Effect of oral milrinone on mortality in severe chronic heart failure. The promise research group. N Engl J Med 1991; 325: 1468-1475
    CrossrefPubMedGoogle Scholar
  • 31 Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trend Pharmacol Sci 1991; 12: 158-163
    CrossrefPubMedGoogle Scholar
  • 32 De ClerckF, Van GorpL, Beetens J, Verheyen A, Janssen PAJ. Arachidonic acid metabolites, ADP and thrombin modulate occlusive thrombus formation over extensive arterial injury in the rat. Blood Coag Fibrinol 1990; 1: 247-258
    CrossrefPubMedGoogle Scholar